Total Funding
1
Total FundingSeries A raised
Growth Score
pts
Heat Score
-8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
NEUWAY is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases
Heiko Manninga: Managing Director, Co-Founder
Stephan Rapp: Co-Founder and CEO
About the Company
NEUWAY Pharma is committed to bringing transformative neuropharmaceuticals across the blood-brain barrier through its EnPC®, the drug delivery technology based on a natural derived protein capsule.
In addition to advancing its proprietary pipeline, the company aims to be a partner of choice in particular for antibody and mRNA drug developers
stymied by the hurdles of delivering these and other drug modalities into the brain and CNS tissue. Operating as a drug developer and a delivery expert, NEUWAY will demonstrate the value of its technology through its internal orphan neurological disease pipeline and partnered programs.
